Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APF530 vs Palonosetron for CINV Prevention
NCT00343460Phase 3Completed
- Sponsor
- Heron Therapeutics, Inc.
- Start
- Jun 2006
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of granisetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Heron Therapeutics, Inc. Primary endpoints: Complete Response During Acute Phase (0-24 Hours) and Complete Response During Delayed-onset Phase (24-120 Hours). Started Jun 2006; status: completed.
02
Drugs
granisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00343460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00343460.